Apr 16, 2020
SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology
Mar 23, 2020
One-Year Outcomes of Real-World RECOVER(TM) Study Published in Journal of Addiction Medicine
Dec 10, 2019
Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder
Dec 02, 2019
New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes
Nov 11, 2019
Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"
Jul 11, 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m
Apr 09, 2019
Citizen Petition Calls on FDA to Revoke Orphan Designation for Sublocade
Mar 07, 2019
The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Feb 20, 2019
Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
Feb 19, 2019
The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Dec 12, 2018
Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling
Nov 27, 2018
Indivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019
Oct 24, 2018
Advocates for Opioid Recovery Applauds SUPPORT Act (H.R. 6) Signing
Sep 07, 2018
FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Jul 31, 2018
Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld
Jun 15, 2018
Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy's Launch "At-Risk"
Jun 14, 2018
FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence
May 31, 2018
Indivior Receives Subpoena from California Department of Insurance
Apr 13, 2018
Patient-Reported Outcomes Data on SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49th Annual Conference
Apr 05, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers